Armata Pharmaceuticals (ARMP) Q4 2025 earnings summary

Executive summary

• Reported a net loss of $173.8 million for 2025, compared to a net loss of $18.9 million in 2024, driven by significant non-cash charges and impairment expenses.

• Fourth quarter 2025 net loss was $124.3 million, compared to net income of $2.6 million in Q4 2024, primarily due to a $105.8 million non-cash loss from changes in fair value of convertible loan and a $5.4 million impairment expense.

• Research and development expenses decreased year-over-year due to lower clinical trial activity and reduced personnel costs.

• The company’s auditor included a going concern explanatory paragraph in the annual report.

Financial highlights

• Grant revenue for 2025 was $4.9 million, down from $5.2 million in 2024.

• Research and development expenses for 2025 were $23.7 million, down from $34.4 million in 2024.

• General and administrative expenses for 2025 were $12.4 million, slightly down from $13.2 million in 2024.

• Impairment expense of $5.4 million recognized in 2025 related to vacated office and R&D space.

• Cash and cash equivalents at year-end 2025 were $14.1 million, compared to $14.8 million at year-end 2024.

Outlook and guidance

• Management highlighted risks and uncertainties regarding the ability to continue as a going concern and the need for additional funding.

• Forward-looking statements caution about risks in clinical development, regulatory approval, and commercialization timelines.